Table 3.
Adjusted multivariate regression analysis of adverse outcomes by prophylaxis type.
| Outcome | OR (95% CI) | P-value |
|---|---|---|
| Death | 0.19 (0.05–0.68) | 0.0108 |
| Any Complication | 0.58 (0.38–0.89) | 0.0105 |
| VTE (PE or DVT) | 0.53 (0.32–0.90) | 0.0155 |
| PE | 0.41 (0.20–0.86) | 0.0143 |
| DVT | 0.68 (0.37–1.33) | 0.239 |
| ARDS | 1.03 (0.41–3.05) | 0.959 |
| Cardiac arrest | 0.23 (0.05–1.12) | 0.059 |
| MI | 0.74 (0.11–6.56) | 0.762 |
| Stroke/CVA | 2.96 (0.35–83.66) | 0.411 |
| Unplanned Intubation | 0.63 (0.25–1.77) | 0.351 |
Reference group for multivariable analysis was prophylactic agent of ‘Unfractionated Heparin’.
VTE: venous thromboembolism, DVT: deep vein thrombosis, PE: pulmonary embolism, ARDS: acute respiratory distress syndrome, MI: myocardial infarction, CVA: cerebrovascular accident.